Abstract
The standard adjuvant treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC) is endocrine therapy (ET). Despite this treatment, 20% of patients will have their disease recur. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors with ET have shown overall survival (OS) benefit in ER-positive, HER2-negative breast cancer in the metastatic setting. Clinical trials are studying the role of oral CDK4/6 inhibitors in the adjuvant treatment of ER-positive, HER2-negative EBC patients who are clinically and pathologically at high risk for recurrence while on standard ET. The monarchE phase III, randomized, controlled trial, looked at one arm of high-risk ER-positive, HER2-negative EBC patients receiving standard ET and the second arm receiving standard ET with a CDK4/6 inhibitor, abemaciclib. Primary endpoint data showed improvement in invasive disease-free survival of 92.2% in the ET and abemaciclib arm vs. 88.7% in the ET arm at 2 years. At 5 years, a preplanned interim analysis showed continued absolute improvement in invasive disease-free survival. Secondary endpoint data for OS have not yet matured. Abemaciclib is approved for use with ET in patients with high-risk, ER-positive, HER2-negative EBC. This article aims to review a case study and the rationale for using oral CDK4/6 inhibitors as adjuvant treatment for this high-risk subset of patients.
References
Abdel-Razeq, H., & Sharaf, B. (2022). Expanding the clinical use of CDK4/6 inhibitors in the treatment of hormone receptor-positive, HER2-negative breast cancer from metastatic setting to adjuvant setting. Drug Design, Development and Therapy, 16, 727–735. https://doi.org/10.2147/DDDT.S356757
Alkabban, F. M., & Ferguson, T. (2023). Breast cancer. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK482286/
Baum, M., Budzar, A., Cuzik, J., Forbes, J., Houghton, J., Howell, A., & Sahmoud, T. (2003). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Cancer, 98(9), 1802–1810. https://doi.org/10.1002/cncr.11745
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F.,…Winer, E. P. (2018). 4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4). Annals of Oncology, 29(8), 1634–1657. https://doi.org/10.1093/annonc/mdy192
Cristofanilli, M., Rugo, H. S., Im, S.-A., Slamon, D. J., Harbeck, N., Bondarenko, I.,…Turner, N. C. (2022). Overall survival with palbociclib and fulvestrant in women with HR+/HER2− ABC: Updated exploratory analyses of PALOMA-3, a double-blind, phase III randomized study. Clinical Cancer Research, 28(16), 3433–3442. https://doi.org/10.1158/1078-0432.CCR-22-0305
Early Breast Cancer Trialists’ Collaborative Group. (1998). Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet, 351(9114), 1451. https://doi.org/10.1016/S0140-6736(97)11423-4
Eli Lilly. (2023). Verzenio (abemaciclib) package insert. https://pi.lilly.com/us/verzenio-uspi.pdf?s=pi
Gnant, M., Dueck, A., Frantal, S., Martin, M., Burstein, H. J., Greil, R.,...Mayer, E. (2022). Adjuvant palbociclib for early breast cancer: The PALLAS trial results (ABCSG-42/AFT-05/BIG-14-03). Journal of Clinical Oncology, 40(3), 282–293. https://doi.org/10.1200/JCO.21.02554
GoodRx. (2023). Verzenio Prices, Coupons & Savings Tips. https://www.goodrx.com/verzenio?c=homepage-lander-sem-7&utm_campaign=127243741&utm_content=7699746781&utm_source=google&utm_medium=cpc&utm_term=kwd-54255549541&gclid=CjwKCAjw36GjBhAkEiwAKwIWydB2bsNbItVWUo3iKSJpVleb5csERKmf_79akr1oOoxX7S43QUr1QRoC0BgQAvD_B
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yoon-Sim, Y., Sonke, G. S., Hart, L.,...O’Shaughnessy, J. (2022). Overall survival with ribociclib plus letrozole in advanced breast cancer. The New England Journal of Medicine, 386(10), 942–950. https://doi.org/10.1056/NEJMoa2114663
Johnston, S., Harbeck, N., Hegg, R., Toi, M., Martin, M., Shao, Z. M.,.. O’Shaughnessy, J. (2020). Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). Journal of Clinical Oncology, 38(34), 3987–3998. https://doi.org/10.1200/JCO.20.02514
Johnston, S. R. D., Toi, M., O’Shaughnessy, J., Rastogi, P., Campone, M., Neven, P.,...Martin, M. (2023). Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): Results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. The Lancet Oncology, 24(1), 77–90. https://doi.org/10.1016/S1470-2045(22)00694-5
Loibl, S., Marmé, F., Martin, M., Untch, M., Bonnefoi, H., Kim, S.-B.,...von Minckwitz, G. (2021). Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer-the Penelope-B trial. Journal of Clinical Oncology, 39(14), 1518–1530. https://doi.org/10.1200/JCO.20.03639
Łukasik, P., Baranowska-Bosiacka, I., Kulczycka, K., & Gutowska, I. (2021). Inhibitors of cyclin-dependent kinases: Types and their mechanism of action. International Journal of Molecular Sciences, 22(6), 2806. https://doi.org/10.3390/ijms22062806
Midatech Pharma. (2018). Soltamox (tamoxifen citrate) package insert. https://soltamox.com/wp-content/uploads/2019/12/soltamox-pi.pdf
National Comprehensive Cancer Network. (2023). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer NCCN Evidence Blocks. V1.2023. https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf
Novartis. (2024). Latest analysis of Novartis NATALEE study shows Kisqali reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease. https://www.novartis.com/news/media-releases/latest-analysis-novartis-natalee-study-shows-kisqali-reduces-risk-cancer-recurrence-early-breast-cancer-patients-high-risk-node-negative-disease
Peters, A., & Tadi, P. (2023). Aromatase Inhibitors. In StatPearls. http://www.ncbi.nlm.nih.gov/books/NBK557856/
Rastogi, P., O’Shaughnessy, J., Martin, M., Boyle, F., Cortes, J., Rugo, H.,...Antonio, B. S. (2024). Adjuvant abemaciclib plus endocrine therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. Journal of Clinical Oncology, 42(9), 987–993. https://doi.org/10.1200/JCO.23.01994
Royce, M., Osgood, C., Mulkey, F., Bloomquist, E., Pierce, W. F., Roy, A.,...Amiri-Kordestani, L. (2022). FDA approval summary: Abemaciclib with endocrine therapy for high-risk early breast cancer. Journal of Clinical Oncology, 40(11), 1155–1162. https://doi.org/10.1200/JCO.21.02742
Slamon, D., Stroyakovskiy, D., Yardley, D., Huang, C.-S., Fasching, P. A., Crown, J.,…Hortobagyi, G. N. (2023). Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial. Journal of Clinical Oncology, 41(17_suppl), LBA500. https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA500
Sledge, G. W., Jr., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X.,…Llombart-Cussac, A. (2020). The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: A randomized clinical trial. JAMA Oncology, 6(1), 116–124. https://doi.org/10.1001/jamaoncol.2019.4782
US Food & Drug Administration. (2021). FDA approves abemaciclib with endocrine therapy for early breast cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-abemaciclib-endocrine-therapy-early-breast-cancer
US National Institutes of Health. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/results?pg=1&load=cart&id=NCT02513394+OR+NCT01864746+OR+NCT03701334
US National Institutes of Health. (2017). A randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, hormone receptor positive, human epidermal receptor 2 negative, breast cancer. Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT03155997
US National Institutes of Health. (2018). A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE). Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT03701334
Watt, A. C., & Goel, S. (2022). Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer. Breast Cancer Research, 24(1), 17. https://doi.org/10.1186/s13058-022-01510-6
